ARMATA PHARMACEUTICALS, INC. Preferred Stock Dividends, Income Statement Impact
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Preferred Stock Dividends, Income Statement Impact of $8.46 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2014-05-20
- ARMATA PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2014-03-31 was $8.46M.
- ARMATA PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2013-03-31 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|
| 2014-03-31 | $8.46M 10-Q · filed 2014-05-20 | |
| 2013-12-31 | $8.46M 10-Q · filed 2014-05-20 | |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |